The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
What Are The Market Size Estimates For The Huntington’s Disease Treatment Market In 2026 And 2030?
The huntington’s disease treatment market size has expanded rapidly in recent years. It is projected to increase from $0.82 billion in 2025 to $0.92 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 12.6%. The historical growth of this market can be attributed to several factors including limited treatment options for neurodegenerative disorders, a rise in the diagnosis of genetic neurological diseases, an early focus on symptomatic management, the expansion of neurology specialty care, and an increase in hospital-based neurological treatments.
The huntington’s disease treatment market size is anticipated to undergo significant expansion in the upcoming years. It is predicted to attain a value of $1.48 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 12.6%. The expansion foreseen during this period can be ascribed to breakthroughs in gene therapy technologies, a rise in funding for rare disease research, an increase in orphan drug designations, greater embrace of precision medicine, and a growing array of disease-modifying therapies in development. Noteworthy trends for the forecast period include an intensified focus on disease-modifying treatments, wider acceptance of gene and RNA-based therapies, broader implementation of combination therapy approaches, an increasing emphasis on creating symptom-specific drugs, and a surge in clinical trial activity for uncommon neurological disorders.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24245&type=smp
What Factors Are Contributing To The Growth Of The Huntington’s Disease Treatment Market?
The expanding presence of gene therapies is anticipated to drive the future growth of the Huntington’s disease treatment market. These therapies involve modifying or replacing flawed genes to prevent or cure illnesses at a genetic level. Their development is accelerating with advancements in precision medicine, allowing for direct targeting of genetic origins and yielding superior results compared to conventional treatments. Specifically for Huntington’s disease, gene therapies function by inactivating the faulty HTT gene, which produces harmful proteins, thereby averting damage to nerve cells. This approach contributes to slowing the disease’s progression, safeguarding brain function, and offers prospects for enduring management. For instance, data from July 2023, provided by the American Society of Gene & Cell Therapy (ASGCT), a US-based professional membership organization, and Citeline, a US-based provider of drugs and devices, indicated that 247 gene therapies were in phase II at the close of Q1 2023, a figure that climbed by 5% to reach 260 by the end of Q2. Consequently, the rising number of gene therapies is propelling the expansion of the Huntington’s disease treatment market.
What Segment Categories Shape The Huntington’s Disease Treatment Market Segment Landscape?
The huntington’s disease treatment market covered in this report is segmented –
1) By Treatment: Symptomatic Treatment, Disease-Modifying Therapies
2) By Administration Type: Oral, Intravenous, Subcutaneous, Topical
3) By Therapeutic: Genetic Disorders, Neurological Disorders, Psychiatric Disorders
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
5) By End-User: Hospitals, Clinics, Homecare Settings, Research Centers
Subsegments:
1) By Symptomatic Treatment: Antidepressants, Antipsychotics, Mood Stabilizers, Chorea Medications, Cognitive Enhancers
2) By Disease-Modifying Therapies: Gene Therapy, Neuroprotective Agents, RNA-Based Therapies, Stem Cell Therapy, Protein-Targeting Therapies
What Trends Are Shaping The Future Of The Huntington’s Disease Treatment Market?
Leading companies within the Huntington’s disease treatment market are concentrating on developing advanced therapies, such as selective vesicular monoamine transporter 2 (VMAT2) inhibitor capsules, with the aim of potentially enhancing patient quality of life and decelerating disease progression. These selective VMAT2 inhibitor capsules are medications designed to obstruct vesicular monoamine transporter 2, a protein crucial for packaging neurotransmitters before their release in the brain. By reducing neurotransmitter release, these drugs assist in managing involuntary movements and related symptoms. For example, in August 2023, Neurocrine Biosciences, Inc., a US-based biotechnology company, secured approval from the U.S. Food and Drug Administration (FDA) for Ingrezza (valbenazine) capsules, intended for the treatment of chorea associated with Huntington’s disease (HD) in adults. These capsules function as a once-daily oral VMAT2 inhibitor, operating by diminishing excessive dopamine signaling in the brain to help regulate involuntary movements. The medication is provided in multiple capsule strengths and can be administered with or without food, thereby offering a convenient dosing option for patients.
Who Are The Companies Operating Across The Huntington’s Disease Treatment Market Value Chain?
Major companies operating in the huntington’s disease treatment market are F. Hoffmann-La Roche Ltd., Novartis AG, Teva Pharmaceutical Industries Ltd., H. Lundbeck A/S, Neurocrine Biosciences Inc., Wave Life Sciences Ltd., PTC Therapeutics Inc., Ionis Pharmaceuticals Inc., uniQure N.V., Prilenia Therapeutics B.V., Sage Therapeutics Inc., Annexon Inc., Alnylam Pharmaceuticals Inc., Sun Pharmaceutical Industries Inc., Dr. Reddy’s Laboratories Ltd., Lupin Limited, Hikma Pharmaceuticals plc, Astellas Pharma Inc., Otsuka Pharmaceutical Co. Ltd., AbbVie Inc.
Get The Full Huntington’s Disease Treatment Market Report:
https://www.thebusinessresearchcompany.com/report/huntingtons-disease-treatment-global-market-report
Which Geographic Region Dominates The Huntington’s Disease Treatment Market?
North America was the largest region in the Huntington’s disease treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the huntington’s disease treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Huntington’s Disease Treatment Market Report For Competitive Insights:
https://www.thebusinessresearchcompany.com/report/huntingtons-disease-treatment-global-market-report
Browse Through More Reports Similar to the Global Huntington’s Disease Treatment Market 2026, By The Business Research Company
Brain Tumor Drugs Market Report 2026
https://www.thebusinessresearchcompany.com/report/brain-tumor-drugs-global-market-report
Brain And Neuroimaging Devices Market Report 2026
Brain Tumor Drugs Market 2026
https://www.thebusinessresearchcompany.com/report/brain-tumor-drugs-global-market
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model